The daily use of specific
antiretroviral medications by persons without HIV, but at high risk
of exposure to HIV, has been shown to be a safe and effective HIV
prevention method. The FDA approved the use of Truvada® for
preexposure prophylaxis (PrEP) and CDC has issued clinical practice
guidelines for its use. CDC requests approval to assess the utility
of new measures developed or adapted to collect information related
to this new intervention and to evaluate community contextual
factors that may impact the acceptability and successful
introduction of a new HIV prevention method. The project will be
conducted in communities where PrEP has become available through a
local community health center - a community-based survey in public
venues in the catchment areas of the PrEP clinics, and key
stakeholder surveys community HIV leaders. The surveys will collect
demographic data, knowledge of PrEP, misinformation about PrEP, and
attitudes about it. This request is to add another clinic and
change 2 of the survey sites.
Request to add respondents due
to adding a clinic to increase respondent diversity, changing some
of the study sites, and a minor wording change in one question.
Burden increase due to increase in respondents.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.